Abbisko Cayman (HKG:2256) said its subsidiary has dosed the first patient in a Phase I trial of ABSK211, an oral pan-KRAS inhibitor for advanced solid tumors with KRAS alterations.
The trial will evaluate the drug's safety, tolerability, efficacy and pharmacokinetics, according to a Sunday Hong Kong bourse filing.
Shares of the company fell nearly 4% in recent trade.